Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label sunitinib continuation study after prior Pfizer parent study
NL-OMON31148Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sunitinib in islet cell tumor and pancreatic cancer (PC), sponsored by Pfizer. Primary endpoint: No formal primary endpoint. Planned start Jul 2007; status: not yet recruiting.
02
Drugs
sunitinib
03
Conditions
islet cell tumorpancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON31148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31148.